SIRT2, though less studied in pancreatic cancer, has emerged as a potential therapeutic target with the discovery of NPD11033, a selective small-molecule inhibitor that induces a conformational change in SIRT2, inhibiting its activity. Here, SIRT2 is linked to pancreatic neoplasm.